U.S. markets closed
  • S&P 500

    4,519.63
    +33.17 (+0.74%)
     
  • Dow 30

    35,457.31
    +198.70 (+0.56%)
     
  • Nasdaq

    15,129.09
    +107.28 (+0.71%)
     
  • Russell 2000

    2,275.91
    +8.07 (+0.36%)
     
  • Crude Oil

    82.97
    +0.01 (+0.01%)
     
  • Gold

    1,769.80
    -0.70 (-0.04%)
     
  • Silver

    23.72
    -0.17 (-0.70%)
     
  • EUR/USD

    1.1639
    +0.0020 (+0.17%)
     
  • 10-Yr Bond

    1.6350
    +0.0510 (+3.22%)
     
  • GBP/USD

    1.3795
    +0.0068 (+0.50%)
     
  • USD/JPY

    114.3800
    +0.0680 (+0.06%)
     
  • BTC-USD

    63,987.24
    +2,308.05 (+3.74%)
     
  • CMC Crypto 200

    1,481.22
    +17.87 (+1.22%)
     
  • FTSE 100

    7,217.53
    +13.70 (+0.19%)
     
  • Nikkei 225

    29,215.52
    +190.06 (+0.65%)
     

Inovio focused on launching global COVID-19 vaccine trial next month - CEO

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Aug 9 (Reuters) - Inovio Pharmaceuticals Inc is focused on launching the global late-stage trial of its COVID-19 vaccine candidate next month, Chief Executive Officer Joseph Kim said during a post-earnings call on Monday.

In May, Inovio said it will begin a global late-stage study of its vaccine candidate, INO-4800, in summer this year, after it was safe, well-tolerated and produced immune response against the new coronavirus in a mid-stage clinical trial.

The company started developing INO-4800 last year, but fell behind rivals after the U.S. Food and Drug Administration put a part of the study on hold for more information on the vaccine delivery device. (Reporting by Mrinalika Roy in Bengaluru and Carl O'Donnell in New York; Editing by Devika Syamnath)